Our office-space closures help ensure community and employee safety
In our effort to slow the spread of COVID-19, PacificSource office locations remain closed. Until further notice, we’re unable to accommodate any walk-in visitors. As always, our Customer Service team is glad to answer your questions by phone or email. Let us know how we can help!
Contact Us

Drug Changes


Here you will find a listing of the drugs that have been changed on our drug list (formulary) for the plan year you select.

To request Medicare Part D prescription drug coverage determinations (including tiering or formulary exception requests) please use the following form:


Atripla Tablet 600-200-300 MG Oral


Post Date:
2/1/2021
Effective Date:
2/1/2021
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Applies To:
All Rx Plans

Alternative Drugs


Drug Tier* Drug Restrictions Therapy Class
Efavirenz-Emtricitab-Tenofovir Tablet 600-200-300 MG Oral Tier 5 QL Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI)
* Please reference your Evidence of Coverage for applicable cost-sharing.

Demser Capsule 250 MG Oral


Post Date:
2/1/2021
Effective Date:
2/1/2021
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Applies To:
All Rx Plans

Alternative Drugs


Drug Tier* Drug Restrictions Therapy Class
metyroSINE Capsule 250 MG Oral Tier 5 PA Cardiovascular Agents, Other
* Please reference your Evidence of Coverage for applicable cost-sharing.

Emtriva Capsule 200 MG Oral


Post Date:
2/1/2021
Effective Date:
2/1/2021
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Applies To:
All Rx Plans

Alternative Drugs


Drug Tier* Drug Restrictions Therapy Class
Emtricitabine Capsule 200 MG Oral Tier 2 QL Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI)
* Please reference your Evidence of Coverage for applicable cost-sharing.

Ferriprox Tablet 500 MG Oral


Post Date:
2/1/2021
Effective Date:
2/1/2021
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Applies To:
All Rx Plans

Alternative Drugs


Drug Tier* Drug Restrictions Therapy Class
Deferiprone Tablet 500 MG Oral Tier 5 PA Electrolyte/Mineral/Metal Modifiers
* Please reference your Evidence of Coverage for applicable cost-sharing.

Kuvan Packet 100 MG Oral


Post Date:
2/1/2021
Effective Date:
2/1/2021
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Applies To:
All Rx Plans

Alternative Drugs


Drug Tier* Drug Restrictions Therapy Class
Sapropterin Dihydrochloride Packet 100 MG Oral Tier 5 PA Genetic or Enzyme or Protein Disorder: Replacement, Modifiers, Treatment
* Please reference your Evidence of Coverage for applicable cost-sharing.

Kuvan Packet 500 MG Oral


Post Date:
2/1/2021
Effective Date:
2/1/2021
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Applies To:
All Rx Plans

Alternative Drugs


Drug Tier* Drug Restrictions Therapy Class
Sapropterin Dihydrochloride Packet 500 MG Oral Tier 5 PA Genetic or Enzyme or Protein Disorder: Replacement, Modifiers, Treatment
* Please reference your Evidence of Coverage for applicable cost-sharing.

Kuvan Tablet Soluble 100 MG Oral


Post Date:
2/1/2021
Effective Date:
2/1/2021
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Applies To:
All Rx Plans

Alternative Drugs


Drug Tier* Drug Restrictions Therapy Class
Sapropterin Dihydrochloride Tablet Soluble 100 MG Oral Tier 5 PA Genetic or Enzyme or Protein Disorder: Replacement, Modifiers, Treatment
* Please reference your Evidence of Coverage for applicable cost-sharing.

MoviPrep Solution Reconstituted 100 GM Oral


Post Date:
2/1/2021
Effective Date:
2/1/2021
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Applies To:
All Rx Plans

Alternative Drugs


Drug Tier* Drug Restrictions Therapy Class
PEG-KCl-NaCl-NaSulf-Na Asc-C Solution Reconstituted 100 GM Oral Tier 2 Anti-Constipation Agents
* Please reference your Evidence of Coverage for applicable cost-sharing.

Symfi Lo Tablet 400-300-300 MG Oral


Post Date:
2/1/2021
Effective Date:
2/1/2021
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Applies To:
All Rx Plans

Alternative Drugs


Drug Tier* Drug Restrictions Therapy Class
Efavirenz-lamiVUDine-Tenofovir Tablet 400-300-300 MG Oral Tier 2 Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI)
* Please reference your Evidence of Coverage for applicable cost-sharing.

Symfi Tablet 600-300-300 MG Oral


Post Date:
2/1/2021
Effective Date:
2/1/2021
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Applies To:
All Rx Plans

Alternative Drugs


Drug Tier* Drug Restrictions Therapy Class
Efavirenz-lamiVUDine-Tenofovir Tablet 600-300-300 MG Oral Tier 2 Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI)
* Please reference your Evidence of Coverage for applicable cost-sharing.

Truvada Tablet 200-300 MG Oral


Post Date:
2/1/2021
Effective Date:
2/1/2021
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Applies To:
All Rx Plans

Alternative Drugs


Drug Tier* Drug Restrictions Therapy Class
Emtricitabine-Tenofovir DF Tablet 200-300 MG Oral Tier 5 QL Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI)
* Please reference your Evidence of Coverage for applicable cost-sharing.

Tykerb Tablet 250 MG Oral


Post Date:
2/1/2021
Effective Date:
2/1/2021
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Applies To:
All Rx Plans

Alternative Drugs


Drug Tier* Drug Restrictions Therapy Class
Lapatinib Ditosylate Tablet 250 MG Oral Tier 5 PA Molecular Target Inhibitors
* Please reference your Evidence of Coverage for applicable cost-sharing.